利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.026 秒)

    Humanized anti-prostate stem cell antigen monoclonal antibody
    1.
    发明授权
    Humanized anti-prostate stem cell antigen monoclonal antibody 有权
    人源化抗前列腺干细胞抗原单克隆抗体

    公开(公告)号：US08088908B2

    公开(公告)日：2012-01-03

    申请号：US11432304

    申请日：2006-05-10

    申请人： Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    发明人： Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    IPC分类号： C07H21/04

    CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

    摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。

    Humanized anti-prostate stem cell antigen monoclonal antibody
    5.
    发明授权
    Humanized anti-prostate stem cell antigen monoclonal antibody 有权
    人源化抗前列腺干细胞抗原单克隆抗体

    公开(公告)号：US08404817B2

    公开(公告)日：2013-03-26

    申请号：US13308783

    申请日：2011-12-01

    申请人： Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    发明人： Mark A. Sherman ,  Anna M. Wu ,  Robert E. Reiter

    IPC分类号： C12P21/08

    CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

    摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。

    HUMANIZED ANTI-PROSTATE STEM CELL ANTIGEN MONOCLONAL ANTIBODY
    6.
    发明申请
    HUMANIZED ANTI-PROSTATE STEM CELL ANTIGEN MONOCLONAL ANTIBODY 有权
    人类抗前列腺癌细胞抗原单克隆抗体

    公开(公告)号：US20120077962A1

    公开(公告)日：2012-03-29

    申请号：US13308783

    申请日：2011-12-01

    申请人： Mark A. SHERMAN ,  Anna M. Wu ,  Robert E. Reiter

    发明人： Mark A. SHERMAN ,  Anna M. Wu ,  Robert E. Reiter

    IPC分类号： C07K16/18 ,  C07K17/00

    CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

    摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。